Business context and reporting period
The supplied filing is CM Life Sciences, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2021—not a filing by GeneDx Holdings Corp. CM Life Sciences was a shell SPAC formed to acquire a business and reported no operating activity or revenue. Its proposed target was Mount Sinai Genomics, Inc., doing business as Sema4.
Financial results and position
- Revenue: None; the company had not begun operations.
- Three months ended June 30, 2021: Net income of $13.0 million, comprising $14.3 million of noncash warrant fair-value gain and $11,040 of trust interest, less $1.28 million of general and administrative expense. Basic Class B earnings per share were $1.18; diluted loss per share was $0.09.
- Six months ended June 30, 2021: Net loss of $45.5 million, including a $42.4 million noncash warrant fair-value loss, $3.12 million of general and administrative expense, and $21,959 of trust interest. Basic and diluted Class B loss per share was $4.11.
- Cash flow: Operating cash used was $926,722 for the six months. Cash outside the trust fell from $1.09 million at December 31, 2020 to $167,959 at June 30, 2021.
- Liquidity and assets: Trust assets were $442.8 million, largely U.S. Treasury money-market investments. Working-capital deficit was $1.85 million. Total assets were $443.2 million.
- Liabilities and debt: Total liabilities were $130.4 million, including $112.7 million of warrant liabilities and $15.5 million of deferred underwriting fees payable upon a completed business combination. No long-term debt or working-capital loans were outstanding.
Changes and notable items
Compared with December 31, 2020, cash outside the trust decreased by $926,722, accounts payable and accrued expenses increased to $2.24 million from $97,120, and warrant liabilities rose to $112.7 million from $70.3 million. The warrant remeasurement drove much of the reported earnings volatility; quarterly profit should not be read as operating performance.
The company had previously restated its financial statements to classify public and private warrants as liabilities. Management said disclosure controls were ineffective as of June 30, 2021 due to that restatement; remediation steps were underway but the issue was not fully remediated.
Outlook, transaction, and risks
- The proposed Sema4 merger was expected to close in the third quarter of 2021 in the notes, while the MD&A says the second quarter; the filing’s stated timing is inconsistent.
- Transaction financing included a $350 million PIPE subscription and potential forward purchases of up to $150 million, subject to conditions. Sema4 shareholders could elect cash consideration up to an aggregate $343 million. Additional earn-out shares of up to 11% were tied to share-price thresholds.
- The company said available sponsor-related borrowing capacity and working-capital resources should cover needs through a business combination or at least one year from issuance of the statements, but sponsor loans were discretionary, not committed. Failure to complete a merger by September 4, 2022 would generally require liquidation and redemption of public shares.
- COVID-19 could adversely affect the company, though the filing said the impact was not determinable. No material change to previously disclosed risk factors was reported. No legal proceedings were reported.
Investor verification points
- Confirm the issuer: this filing is for CM Life Sciences, Inc., not GeneDx Holdings Corp.
- Check the Sema4 transaction’s actual closing status, final cash elections, redemptions, and financing proceeds; the filing’s expected closing quarter conflicts internally.
- Assess the warrant liability’s fair-value assumptions and its effect on reported earnings.
- Review progress in remediating the material weakness in disclosure controls.
- Verify cash available outside the trust and whether any discretionary sponsor or other financing was ultimately provided.